Logo

Atugen Raises 5M for Developing siRNA Therapeutics

Mar 15, 2004

NEW YORK, March 15 (GenomeWeb News) - RNAi firm Atugen has raised €5 million in a third financing round, the company said today.

 

The financing round was managed by WestLBPanmure and co-led by new investor Novartis Venture Fund and funds advised by Apax Partners. Previous investor MPM Capital also joined the round.

 

Atugen, based in Berlin, Germany, is developing siRNA therapeutics.

Breaking News
The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.